# Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

> **NCT00751790** · PHASE3 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 120 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** triptorelin embonate (INN)

## Key facts

- **NCT ID:** NCT00751790
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751790, "Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00751790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*